Medicine

Citius Pharmaceuticals Resubmits BLA for Lymphir to Address FDA Complete Response Letter

Lymphir is an immunotherapy under evaluation for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma following at least one previous line of systemic therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *